Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
New therapeutic strategies for malignant mesothelioma are urgently needed. In the DETERMINE study, we investigated the effects of the cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody tremelimumab in patients with previously treated advanced malignant mesothelioma.
Gespeichert in:
| Veröffentlicht in: | The Lancet Oncology 2017-09, Vol.18 (9), p.1261-1273 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1273 |
|---|---|
| container_issue | 9 |
| container_start_page | 1261 |
| container_title | The Lancet Oncology |
| container_volume | 18 |
| creator | Maio, Michele Scherpereel, Arnaud Calabrò, Luana Aerts, Joachim Perez, Susana Cedres Bearz, Alessandra Nackaerts, Kristiaan Fennell, Dean A Kowalski, Dariusz Tsao, Anne S Taylor, Paul Grosso, Federica Antonia, Scott J Nowak, Anna K Taboada, Maria Puglisi, Martina Stockman, Paul K Kindler, Hedy L |
| description | New therapeutic strategies for malignant mesothelioma are urgently needed. In the DETERMINE study, we investigated the effects of the cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody tremelimumab in patients with previously treated advanced malignant mesothelioma. |
| format | Article |
| fullrecord | <record><control><sourceid>kuleuven</sourceid><recordid>TN_cdi_kuleuven_dspace_123456789_593042</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>123456789_593042</sourcerecordid><originalsourceid>FETCH-kuleuven_dspace_123456789_5930423</originalsourceid><addsrcrecordid>eNqVjr1OxDAQhFOAxAH3DtsBIpGcP8LRQhAUUJzSR5tkIYa1HdkO4uV4N7a4B4BqNauZb-Yo2eRVo7JCVfVJchrCh1J5k6t6k_x0ngyxNqvBATBAoNHZKWNtCZyHOGt_UNETRkM2grbgiXEJNIFB1u8W5WsouDgLyxmEy4e2a_cvz6_t1R0gmJWjHiXrKZV4JG8xameRU_BoJ2e0wFKY3DowZYMUiloYRxpcJouid8xSt8wYCIpB1mjk8-T4DTnQ9nDPkovHtrt_yj5XpvWLbD-FRRh9XpRVfdPc7vp6V6qqKP_jvP6bs4_fsfwFcPt0nQ</addsrcrecordid><sourcetype>Institutional Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial</title><source>Lirias (KU Leuven Association)</source><source>ScienceDirect Journals (5 years ago - present)</source><source>ProQuest Central UK/Ireland</source><creator>Maio, Michele ; Scherpereel, Arnaud ; Calabrò, Luana ; Aerts, Joachim ; Perez, Susana Cedres ; Bearz, Alessandra ; Nackaerts, Kristiaan ; Fennell, Dean A ; Kowalski, Dariusz ; Tsao, Anne S ; Taylor, Paul ; Grosso, Federica ; Antonia, Scott J ; Nowak, Anna K ; Taboada, Maria ; Puglisi, Martina ; Stockman, Paul K ; Kindler, Hedy L</creator><creatorcontrib>Maio, Michele ; Scherpereel, Arnaud ; Calabrò, Luana ; Aerts, Joachim ; Perez, Susana Cedres ; Bearz, Alessandra ; Nackaerts, Kristiaan ; Fennell, Dean A ; Kowalski, Dariusz ; Tsao, Anne S ; Taylor, Paul ; Grosso, Federica ; Antonia, Scott J ; Nowak, Anna K ; Taboada, Maria ; Puglisi, Martina ; Stockman, Paul K ; Kindler, Hedy L</creatorcontrib><description>New therapeutic strategies for malignant mesothelioma are urgently needed. In the DETERMINE study, we investigated the effects of the cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody tremelimumab in patients with previously treated advanced malignant mesothelioma.</description><identifier>ISSN: 1470-2045</identifier><language>eng</language><publisher>Lancet Pub. Group</publisher><ispartof>The Lancet Oncology, 2017-09, Vol.18 (9), p.1261-1273</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,315,780,784,27859</link.rule.ids></links><search><creatorcontrib>Maio, Michele</creatorcontrib><creatorcontrib>Scherpereel, Arnaud</creatorcontrib><creatorcontrib>Calabrò, Luana</creatorcontrib><creatorcontrib>Aerts, Joachim</creatorcontrib><creatorcontrib>Perez, Susana Cedres</creatorcontrib><creatorcontrib>Bearz, Alessandra</creatorcontrib><creatorcontrib>Nackaerts, Kristiaan</creatorcontrib><creatorcontrib>Fennell, Dean A</creatorcontrib><creatorcontrib>Kowalski, Dariusz</creatorcontrib><creatorcontrib>Tsao, Anne S</creatorcontrib><creatorcontrib>Taylor, Paul</creatorcontrib><creatorcontrib>Grosso, Federica</creatorcontrib><creatorcontrib>Antonia, Scott J</creatorcontrib><creatorcontrib>Nowak, Anna K</creatorcontrib><creatorcontrib>Taboada, Maria</creatorcontrib><creatorcontrib>Puglisi, Martina</creatorcontrib><creatorcontrib>Stockman, Paul K</creatorcontrib><creatorcontrib>Kindler, Hedy L</creatorcontrib><title>Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial</title><title>The Lancet Oncology</title><description>New therapeutic strategies for malignant mesothelioma are urgently needed. In the DETERMINE study, we investigated the effects of the cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody tremelimumab in patients with previously treated advanced malignant mesothelioma.</description><issn>1470-2045</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>FZOIL</sourceid><recordid>eNqVjr1OxDAQhFOAxAH3DtsBIpGcP8LRQhAUUJzSR5tkIYa1HdkO4uV4N7a4B4BqNauZb-Yo2eRVo7JCVfVJchrCh1J5k6t6k_x0ngyxNqvBATBAoNHZKWNtCZyHOGt_UNETRkM2grbgiXEJNIFB1u8W5WsouDgLyxmEy4e2a_cvz6_t1R0gmJWjHiXrKZV4JG8xameRU_BoJ2e0wFKY3DowZYMUiloYRxpcJouid8xSt8wYCIpB1mjk8-T4DTnQ9nDPkovHtrt_yj5XpvWLbD-FRRh9XpRVfdPc7vp6V6qqKP_jvP6bs4_fsfwFcPt0nQ</recordid><startdate>201709</startdate><enddate>201709</enddate><creator>Maio, Michele</creator><creator>Scherpereel, Arnaud</creator><creator>Calabrò, Luana</creator><creator>Aerts, Joachim</creator><creator>Perez, Susana Cedres</creator><creator>Bearz, Alessandra</creator><creator>Nackaerts, Kristiaan</creator><creator>Fennell, Dean A</creator><creator>Kowalski, Dariusz</creator><creator>Tsao, Anne S</creator><creator>Taylor, Paul</creator><creator>Grosso, Federica</creator><creator>Antonia, Scott J</creator><creator>Nowak, Anna K</creator><creator>Taboada, Maria</creator><creator>Puglisi, Martina</creator><creator>Stockman, Paul K</creator><creator>Kindler, Hedy L</creator><general>Lancet Pub. Group</general><scope>FZOIL</scope></search><sort><creationdate>201709</creationdate><title>Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial</title><author>Maio, Michele ; Scherpereel, Arnaud ; Calabrò, Luana ; Aerts, Joachim ; Perez, Susana Cedres ; Bearz, Alessandra ; Nackaerts, Kristiaan ; Fennell, Dean A ; Kowalski, Dariusz ; Tsao, Anne S ; Taylor, Paul ; Grosso, Federica ; Antonia, Scott J ; Nowak, Anna K ; Taboada, Maria ; Puglisi, Martina ; Stockman, Paul K ; Kindler, Hedy L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-kuleuven_dspace_123456789_5930423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maio, Michele</creatorcontrib><creatorcontrib>Scherpereel, Arnaud</creatorcontrib><creatorcontrib>Calabrò, Luana</creatorcontrib><creatorcontrib>Aerts, Joachim</creatorcontrib><creatorcontrib>Perez, Susana Cedres</creatorcontrib><creatorcontrib>Bearz, Alessandra</creatorcontrib><creatorcontrib>Nackaerts, Kristiaan</creatorcontrib><creatorcontrib>Fennell, Dean A</creatorcontrib><creatorcontrib>Kowalski, Dariusz</creatorcontrib><creatorcontrib>Tsao, Anne S</creatorcontrib><creatorcontrib>Taylor, Paul</creatorcontrib><creatorcontrib>Grosso, Federica</creatorcontrib><creatorcontrib>Antonia, Scott J</creatorcontrib><creatorcontrib>Nowak, Anna K</creatorcontrib><creatorcontrib>Taboada, Maria</creatorcontrib><creatorcontrib>Puglisi, Martina</creatorcontrib><creatorcontrib>Stockman, Paul K</creatorcontrib><creatorcontrib>Kindler, Hedy L</creatorcontrib><collection>Lirias (KU Leuven Association)</collection><jtitle>The Lancet Oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maio, Michele</au><au>Scherpereel, Arnaud</au><au>Calabrò, Luana</au><au>Aerts, Joachim</au><au>Perez, Susana Cedres</au><au>Bearz, Alessandra</au><au>Nackaerts, Kristiaan</au><au>Fennell, Dean A</au><au>Kowalski, Dariusz</au><au>Tsao, Anne S</au><au>Taylor, Paul</au><au>Grosso, Federica</au><au>Antonia, Scott J</au><au>Nowak, Anna K</au><au>Taboada, Maria</au><au>Puglisi, Martina</au><au>Stockman, Paul K</au><au>Kindler, Hedy L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial</atitle><jtitle>The Lancet Oncology</jtitle><date>2017-09</date><risdate>2017</risdate><volume>18</volume><issue>9</issue><spage>1261</spage><epage>1273</epage><pages>1261-1273</pages><issn>1470-2045</issn><abstract>New therapeutic strategies for malignant mesothelioma are urgently needed. In the DETERMINE study, we investigated the effects of the cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody tremelimumab in patients with previously treated advanced malignant mesothelioma.</abstract><pub>Lancet Pub. Group</pub></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1470-2045 |
| ispartof | The Lancet Oncology, 2017-09, Vol.18 (9), p.1261-1273 |
| issn | 1470-2045 |
| language | eng |
| recordid | cdi_kuleuven_dspace_123456789_593042 |
| source | Lirias (KU Leuven Association); ScienceDirect Journals (5 years ago - present); ProQuest Central UK/Ireland |
| title | Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T01%3A18%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kuleuven&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tremelimumab%20as%20second-line%20or%20third-line%20treatment%20in%20relapsed%20malignant%20mesothelioma%20(DETERMINE):%20a%20multicentre,%20international,%20randomised,%20double-blind,%20placebo-controlled%20phase%202b%20trial&rft.jtitle=The%20Lancet%20Oncology&rft.au=Maio,%20Michele&rft.date=2017-09&rft.volume=18&rft.issue=9&rft.spage=1261&rft.epage=1273&rft.pages=1261-1273&rft.issn=1470-2045&rft_id=info:doi/&rft_dat=%3Ckuleuven%3E123456789_593042%3C/kuleuven%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |